A Phase 2 interventional study of ALX-0171 Dose 1 and ALX-0171 Dose 2 in Respiratory Syncytial Virus Lower Respiratory Tract Infection, sponsored by Ablynx, a Sanofi company. Withdrawn at 5 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-11.
Sponsored by Ablynx, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the antiviral effect and safety of inhaled ALX-0171 in adults diagnosed with respiratory syncytial virus (RSV) respiratory tract infection after hematopoietic stem cell transplantation (HSCT).
The secondary objective is to assess the clinical activity, pharmacokinetics (PK), virology, and immunogenicity of inhaled ALX 0171 in adults diagnosed with RSV respiratory tract infection after HSCT.
Ablynx, a Sanofi company is the lead sponsor of 25 studies on the registry; none are open to participants now.
First submitted before Ablynx became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has:
Others as defined in the protocol
Exclusion Criteria:
Others as defined in the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ALX-0171 Dose 1
Biological: ALX-0171 Dose 2
Biological: Placebo
Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
Oral inhalation of Placebo once daily for a maximum of 14 days
Time-weighted average change from baseline in log10 RSV nasal viral load
Time frame: From Day 1 to Day 7
Safety as measured by the incidence of treatment-emergent (serious) adverse events
Time frame: From Screening to Day 42
Nasal RSV load parameter: time to undetectable shedding
Time frame: From Day 1 to Day 42
Clinical stabilization (defined as respiratory rate <25/minute and stable oxygen saturation >92% on room air for at least 12 hours)
Time frame: From Day 1 to Day 42
Number of days without oxygen or with oxygen supplementation
Time frame: From Day 1 to Day 42
Progression to lower respiratory tract (LRT) disease in subjects presenting with upper respiratory tract infection (URTI) at baseline
Time frame: From Day 1 to Day 42
Concentration of ALX-0171 in serum
Measurement of ALX-0171 serum concentration at different time points from baseline until Day 14.
Time frame: Day 1 to Day 14
Immunogenicity as measured by the concentration of anti-ALX 0171 antibodies in serum
Time frame: From Day 1 to Day 42
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2019; primary completion for May 2020, 15 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gontivimab